ANIARA
DIAGNOSTICA INC

YOUR LAB DESERVES A PARTNER.
Not a vendor.

FACTOR XIA ACTIVITY · CHROMOGENIC · THE FACTOR XI(A) ANTICOAGULANT ERA

Factor XIa — the next anticoagulant target, *measured.*

The next wave of anticoagulants targets **Factor XI** and its active form, **FXIa** — abelacimab, asundexian, milvexian and others — aiming to prevent thrombosis while sparing hemostasis. As these agents advance, the field **urgently needs reliable ways to measure FXIa activity and its inhibition.** The BIOPHEN™ Factor XIa chromogenic assay does exactly that.

ACTIVATED FXI (FXIA) ACTIVITY · CHROMOGENIC

BIOPHEN™ Factor XIa

- Measures **FXIa activity** through a coupled cascade — FXIa activates Factor IX, driving **Factor Xa generation** read on a chromogenic substrate.
- Signal is **proportional to FXIa activity**; kit includes a dedicated **FXIa calibrator**.
- Quantifies FXIa and **resolves the inhibitory effect** of FXI/FXIa-directed agents.
- Manual or automated · **2 × 3 mL**.

A220412 — $593
RESEARCH USE ONLY

WHY FACTOR XIA, AND WHY NOW

Inhibiting FXI/FXIa **uncouples thrombosis from hemostasis** — the goal is effective anticoagulation with **less bleeding** than FXa- or FIIa-directed DOACs.

The measurement gap: PT, fibrinogen and FII/V/VII/X are largely **unaffected**; APTT prolongs but is **nonspecific and unstandardized** — a dedicated FXIa assay fills the PD gap.

Pipeline — monoclonal antibodies (abelacimab, osocimab, xisomab), oral small molecules (asundexian, milvexian), antisense (fesomersen).

HOW IT WORKS — FXIa in the sample activates **Factor IX** → FIXa, which (with FVIIIa, phospholipid & Ca^{2+}) activates **Factor X** → FXa; FXa then cleaves a **chromogenic substrate**, releasing color in proportion to FXIa activity. Reading against the FXIa calibrator yields quantitative FXIa — or, with an inhibitor present, the degree of inhibition.

RESEARCH & DEVELOPMENT APPLICATIONS

- FXI(a)-inhibitor drug discovery
- PK / PD characterization
- Inhibition (IC_{50} / K_i) studies
- Assay development
- Contact-pathway & thrombosis research
- FXI activation studies

IN DEVELOPMENT

Coming — drug-specific calibrators & controls for Factor XIa inhibitors. Aniara is developing a dedicated calibrator-and-control set for the FXIa-inhibitor class, for quantitative measurement of agents such as asundexian and milvexian. Ask us at our booth.

Complete the cascade — BIOPHEN™ Factor IX chromogenic (A221802) · BIOPHEN™ Factor X chromogenic (A221705)

SELECTED REFERENCES BIOPHEN™ Factor XIa kit (cat. #220412) used to assess anti-FXI(a) antibody inhibition of FXa generation — US Pat. 12,304,969. · "Anticoagulant drugs targeting factor XI/XIa and coagulation tests: we urgently need reliable pharmacodynamic data" — *Thromb. Res.* 2025. · Multicenter assessment of abelacimab, asundexian & milvexian on coagulation assays (23 laboratories) — *Res. Pract. Thromb. Haemost.* 2026.

Aniara Diagnostica, Inc.
WEST CHESTER, OHIO · 1-866-783-3797

aniara.com
SEARCH "FACTOR XIA" · OR ASK YOUR ANIARA REP

HYPHEN BioMed — Aniara Diagnostica, Inc. is a distributor for HYPHEN BioMed